Lynn Feun
University of Miami · University of Miami Sylvester Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lynn Feun as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:14 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06627244 · Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal MelanomaUniversity of Miami · recruiting · Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver · principal investigator
- Ph2NCT02658019 · Pembrolizumab (Keytruda) in Advanced Hepatocellular CarcinomaLynn Feun, MD · completed · Hepatocellular Carcinoma · principal investigator
- Ph2NCT01639352 · Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular CarcinomaLynn Feun · completed · Hepatocellular Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Arginine Deprivation: A targeted therapy for MelanomaR01CA109578 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · fiscal years 2004 to 2006 · $199,719 awarded in 2006Same name and institution; not confirmed by an ID
- NEW THERAPEUTIC APPROACHES FOR MALIGNANT GLIOMAP20CA060174 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · fiscal years 1993 to 1995 · $73,664 awarded in 1995Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:14 UTC. The ranking covers the 200 most relevant of 43 PubMed records, and a shared surname and initials can bring in a namesake. All 43 on PubMed
- First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.Cancer Discov · 2019230 citationsRCR 8.0
- Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.J Clin Oncol · 2007196 citationsRCR 4.8
- Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.J Clin Oncol · 2005192 citationsRCR 3.9
- 165 citationsRCR 3.8
- 146 citationsRCR 2.9
- 142 citationsRCR 4.8
- Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.J Clin Oncol · 2015113 citationsRCR 4.2
- Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule.Cancer Chemother Pharmacol · 200291 citationsRCR 2.4
- Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.J Natl Cancer Inst · 199584 citationsRCR 1.6
- A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study.Am J Clin Oncol · 199357 citationsRCR 1.3